ASMB · Insider Trading
Assembly Biosciences, Inc
Every open-market purchase and sale reported by ASMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Jeanette M Bjorkquist | PFO and PAO | Sell | −29 | −$674 |
| 2026-06-05 | Gina Consylman | Director | A | +8,000 deriv. | — |
| 2026-06-05 | Anthony E Altig | Director | A | +8,000 deriv. | — |
| 2026-06-05 | Susan Mahony | Director | A | +8,000 deriv. | — |
| 2026-06-05 | Jeanette M Bjorkquist | PFO and PAO | A | +3,500 | — |
| 2026-06-05 | William E Delaney IV | Chief Scientific Officer | A | +14,000 | — |
| 2026-06-05 | John G McHutchison | Director | A | +8,000 deriv. | — |
| 2026-06-05 | Nicole S White | Chief Manufacturing Officer | A | +14,000 | — |
| 2026-06-05 | Michael Houghton | Director | A | +8,000 deriv. | — |
| 2026-06-05 | Jason A Okazaki | CEO and President | A | +50,750 | — |
| 2026-06-05 | Lisa Johnson-Pratt | Director | A | +8,000 deriv. | — |
| 2026-06-05 | Anuj Gaggar | Chief Medical Officer | A | +14,000 | — |
| 2026-05-27 | GILEAD SCIENCES, INC. | 10%+ Owner | A | +471,698 | +$12.50M |
| 2025-10-03 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | +2,295,920 | — |
| 2025-06-17 | Jeanette M Bjorkquist | PFO and PAO | A | +300 | — |
| 2025-06-09 | Gina Consylman | Director | A | +3,500 deriv. | — |
| 2025-06-09 | Michael Houghton | Director | A | +3,500 deriv. | — |
| 2025-06-09 | Susan Mahony | Director | A | +3,500 deriv. | — |
| 2025-06-09 | Lisa Johnson-Pratt | Director | A | +3,500 deriv. | — |
| 2025-06-09 | John G McHutchison | Director | A | +3,500 deriv. | — |
| 2025-06-09 | William R Ringo | Director | A | +3,500 deriv. | — |
| 2025-06-09 | Anthony E Altig | Director | A | +3,500 deriv. | — |
| 2025-04-15 | John G McHutchison | Director | Sell | −757 | −$7.46K |
| 2025-04-01 | Jason A Okazaki | CEO and President | Sell | −355 | −$3.50K |
| 2025-04-01 | Anuj Gaggar | Chief Medical Officer | A | +24,200 deriv. | — |
| 2025-04-01 | Jeanette M Bjorkquist | Principal Accounting Officer | MIXED | +1,475 | −$1.77K |
| 2025-04-01 | Nicole S White | Chief Manufacturing Officer | Sell | −197 | −$1.94K |
| 2025-04-01 | William E Delaney IV | Chief Scientific Officer | A | — | — |
| 2024-12-31 | Michael Houghton | Director | Buy | +3,202 | +$50.00K |
| 2024-12-23 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | +940,499 | +$20.10M |
| 2024-11-26 | Alexander Schornstein | 10%+ Owner | Buy | +25,000 | +$371.99K |
| 2024-11-19 | Nicole S White | Chief Manufacturing Officer | Sell | −40 | −$652 |
| 2024-10-09 | Alexander Schornstein | 10%+ Owner | Buy | +10,000 | +$145.80K |
| 2024-10-04 | Nicole S White | Chief Manufacturing Officer | Sell | −157 | −$2.33K |
| 2024-10-04 | Jason A Okazaki | CEO and President | Sell | −197 | −$2.92K |
| 2024-08-05 | Nicole S White | Chief Manufacturing Officer | Sell | −785 | −$11.17K |
| 2024-08-05 | Jason A Okazaki | CEO and President | Sell | −981 | −$13.96K |
| 2024-07-08 | Alexander Schornstein | 10%+ Owner | Buy | +9,000 | +$111.63K |
| 2024-06-20 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | +179,500 | — |
| 2024-05-30 | Gina Consylman | Director | A | +2,750 deriv. | — |
| 2024-05-30 | Michael Houghton | Director | A | +2,750 deriv. | — |
| 2024-05-30 | William R Ringo | Director | A | +2,750 deriv. | — |
| 2024-05-30 | Anthony E Altig | Director | A | +2,750 deriv. | — |
| 2024-05-30 | John G McHutchison | Director | A | +2,750 deriv. | — |
| 2024-05-30 | Lisa Johnson-Pratt | Director | A | +2,750 deriv. | — |
| 2024-05-30 | Susan Mahony | Director | A | +2,750 deriv. | — |
| 2024-05-24 | Nicole S White | Chief Manufacturing Officer | Sell | −172 | −$2.57K |
| 2024-05-24 | Jason A Okazaki | CEO and President | Sell | −549 | −$8.20K |
| 2024-05-24 | John G McHutchison | Director | Sell | −2,117 | −$31.61K |
| 2024-05-24 | Jeanette M Bjorkquist | Principal Accounting Officer | Sell | −24 | −$358 |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | 4,977,089 | $97.90M |
| Alexander Schornstein | 10%+ Owner | 720,137 | $14.17M |
| Jason A Okazaki | CEO and President | 163,354 | $3.21M |
| William E Delaney IV | Chief Scientific Officer | 60,330 | $1.19M |
| Nicole S White | Chief Manufacturing Officer | 48,145 | $947.01K |
| Anuj Gaggar | Chief Medical Officer | 42,688 | $839.67K |
| John G McHutchison | Director | 18,347 | $360.89K |
| Jeanette M Bjorkquist | PFO and PAO | 14,560 | $286.40K |
| Michael Houghton | Director | 3,202 | $62.98K |
| William R Ringo | Director | 1,455 | $28.62K |
| Anthony E Altig | Director | 667 | $13.12K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASMB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.